Fintel reports that on March 4, 2025, Leerink Partners downgraded their outlook for Lexicon Pharmaceuticals (NasdaqGS:LXRX) ...

Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-opioid pain prospect. | Lexicon Pharmaceuticals ...

The company has chosen to move ahead to Phase III trials with its 10mg dose after it saw a 1.74-point reduction in pain score ...

Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

Lexicon Pharmaceuticals shares are trading lower by 48% Monday morning. The company earlier announced topline results from ...

Leerink analyst Roanna Ruiz downgraded Lexicon (LXRX) to Market Perform from Outperform with a price target of $1, down from $2. The “modest” ...

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They ...

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Acelyrin rejected a bid by Concentra and Atara cut staff.

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report) today and set a price ...

Shares of Lexicon Pharmaceuticals , Inc. (Nasdaq: NASDAQ: LXRX) plummeted 50% following the announcement of topline results from its Phase 2b PROGRESS study, which evaluated the efficacy of ...

Investing.com -- Shares of Lexicon Pharmaceuticals , Inc. (NASDAQ: LXRX) tumbled 55% after the company announced topline results from its PROGRESS Phase 2b study, which evaluated pilavapadin in ...

Pilavapadin achieved meaningful pain reduction versus placebo and was well-tolerated in the 10 mg dose, meeting the Company’s objectives for the study ...